Agios Pharmaceuticals AGIO Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The official record: Agios Pharmaceuticals’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →
Ask your AI about Agios Pharmaceuticals's investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Agios Pharmaceuticals's investing cash flow?
- Agios Pharmaceuticals (AGIO) reported investing cash flow of $141.31M in Q1 2026.
- How has Agios Pharmaceuticals's investing cash flow changed year-over-year?
- Agios Pharmaceuticals's investing cash flow increased by 25.5% year-over-year, from $112.59M to $141.31M.
- What is the long-term trend for Agios Pharmaceuticals's investing cash flow?
- Over 2 years (2022 to 2025), Agios Pharmaceuticals's investing cash flow has grown at a 24.5% compound annual growth rate (CAGR), from $243.26M to $377.18M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.